Mariner LLC Purchases 1,972 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)

Mariner LLC increased its holdings in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) by 5.8% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 35,908 shares of the company’s stock after purchasing an additional 1,972 shares during the quarter. Mariner LLC’s holdings in ARS Pharmaceuticals were worth $379,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently modified their holdings of the company. KLP Kapitalforvaltning AS purchased a new position in ARS Pharmaceuticals during the fourth quarter valued at $73,000. Compass Capital Corp MA ADV purchased a new stake in ARS Pharmaceuticals in the fourth quarter worth approximately $106,000. Teacher Retirement System of Texas bought a new stake in shares of ARS Pharmaceuticals in the fourth quarter worth $122,000. Amica Mutual Insurance Co. bought a new stake in shares of ARS Pharmaceuticals during the 4th quarter valued at about $151,000. Finally, SBI Securities Co. Ltd. purchased a new stake in ARS Pharmaceuticals during the fourth quarter valued at approximately $175,000. Hedge funds and other institutional investors own 68.16% of the company’s stock.

ARS Pharmaceuticals Stock Performance

NASDAQ SPRY opened at $14.46 on Friday. The stock has a 50-day simple moving average of $12.81 and a two-hundred day simple moving average of $13.04. The firm has a market capitalization of $1.42 billion, a P/E ratio of -28.35 and a beta of 0.86. ARS Pharmaceuticals, Inc. has a fifty-two week low of $7.55 and a fifty-two week high of $18.51.

ARS Pharmaceuticals (NASDAQ:SPRY) last announced its earnings results on Thursday, March 20th. The company reported $0.52 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.56. The business had revenue of $86.58 million for the quarter, compared to analysts’ expectations of $15.46 million. As a group, analysts forecast that ARS Pharmaceuticals, Inc. will post -0.55 earnings per share for the current year.

Insider Activity

In other news, insider Eric Karas sold 10,000 shares of the stock in a transaction on Thursday, March 20th. The stock was sold at an average price of $14.00, for a total value of $140,000.00. Following the sale, the insider now directly owns 7,696 shares in the company, valued at approximately $107,744. This trade represents a 56.51 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Laura Shawver sold 49,600 shares of ARS Pharmaceuticals stock in a transaction that occurred on Thursday, March 6th. The stock was sold at an average price of $11.21, for a total transaction of $556,016.00. Following the completion of the transaction, the director now owns 210,346 shares of the company’s stock, valued at $2,357,978.66. This represents a 19.08 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 159,602 shares of company stock worth $1,926,541 over the last ninety days. Corporate insiders own 40.10% of the company’s stock.

Analysts Set New Price Targets

SPRY has been the topic of several recent analyst reports. Oppenheimer initiated coverage on shares of ARS Pharmaceuticals in a research report on Monday, February 10th. They set an “outperform” rating and a $40.00 price objective on the stock. Leerink Partners upped their price objective on ARS Pharmaceuticals from $26.00 to $27.00 and gave the stock an “outperform” rating in a report on Monday, January 13th. Scotiabank assumed coverage on shares of ARS Pharmaceuticals in a report on Friday, March 7th. They issued a “sector outperform” rating and a $30.00 price target for the company. William Blair restated an “outperform” rating on shares of ARS Pharmaceuticals in a research report on Monday, March 3rd. Finally, Raymond James boosted their target price on ARS Pharmaceuticals from $26.00 to $28.00 and gave the company a “strong-buy” rating in a research report on Tuesday, January 14th. Five equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $31.00.

About ARS Pharmaceuticals

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.